Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

Article Abstract:

The search for effective treatments for AIDS has focused on the biology of the human immunodeficiency viruses (HIV). A new set of organic chemical compounds, called TIBO derivatives for brevity, seems to be effective in suppressing the replication of HIV-1, the main etiological agent of AIDS, but not HIV-2 or other viruses tested. These chemical agents are unusual in that, unlike many antiviral agents, the suppression is highly specific for a particular virus. In direct contrast to AZT, a current AIDS therapeutic agent being given widespread trials, the dosage of TIBO compounds necessary to suppress the virus in tissue culture is 10,000 to 100,000 times less than the toxic dose. The effective dose of AZT in tissue culture is only 100 to 10,000 times less than the toxic dose. Clearly, the less toxic the effective dose, the easier it is for clinicians to maintain effective blood concentrations of the therapeutic agent in their patients. Although TIBO derivatives have not yet been tried in AIDS patients, preliminary studies in healthy male volunteers show that no adverse affects were seen at doses 1,000 times greater than the IC-50 (that dose necessary to suppress half the HIV-1 in tissue culture cells). A 200 mg dose resulted in blood levels exceeding the IC-50 for over 24 hours. No significant laboratory changes were observed in these volunteers and the drugs seem to be well tolerated, setting the stage for preliminary evaluations in AIDS patients. (Consumer Summary produced by Reliance Medical Information, Inc.)

Drug therapy, HIV (Viruses), HIV, AIDS (Disease), Virus replication

---

Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection

Article Abstract:

The effectiveness of post-exposure smallpox vaccination and antiviral treatment with either cidofovir or with a related acyclic nucleoside phosphonate analogue after lethal intratracheal infection of cynomolgus monkeys with monkeypox virus is compared. The comparison shows that adequate preparedness for a biological threat involving smallpox should include the possibility of treating exposed individuals with antiviral compounds such as cidofovir or other selective anti-poxvirus drugs.

United States, Care and treatment, Comparative analysis, Dosage and administration, Smallpox vaccine, Smallpox vaccines, Human monkeypox, Monkeypox

---

HTLV-II among pygmies

Article Abstract:

The discovery that human t-cell lymphotrophic virus-II (HTLV-II) infections are endemic among the Efe pygmy tribe in northeastern Zaire disproves the hypothesis that HTLV-II is strictly a New World virus and that HTLV-I is strictly an Old World virus. Tests of sera samples from 12 Efe men found 4 were infected with HTLV-II. Hence the African pygmies as well as the American Indians should be regarded as indigenous populations harboring HTLV-II infection.

Diseases, Pygmies, HTLV-I (Virus), HTLV-II (Virus), Efe (African people)

Similar abstracts:

• Abstracts: Genetics and the making of Homo sapiens. Gene duplication and the adaptive evolution of a classic genetic switch
• Abstracts: Natural forest management and conservation of biodiversity in tropical forests
• Abstracts: Prospective infanticide and ovulation retardation in free-living house sparrows. A test of the hypothesis of mate choice based on heterozygosity in the spotless starling
• Abstracts: Extinction and colonization of birds on habitat islands. The colony structure and population biology of invasive ants
• Abstracts: Transgenic route runs into sand. Particle physics in slivers of mica. Who needs a new magnetometer?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.